Global burden of #VTE: Unknown and underexplored for too long. Need concerted efforts to understand it. We summarize some 🗝️challenges and ways to address them in a @jaccjournals.bsky.social Viewpoint:

www.jacc.org/doi/10.1016/...

Summary of the guideline recs for #anticoagulant & #antiplatelet therapy in ACS c/w prior recs in @americanheart.bsky.social @accintouch.bsky.social and @escardio.bsky.social guidelines. Thankful to Writing Committee & also a great team who made this summary possible:
www.jacc.org/doi/10.1016/...

Must do better for #PE risk stratification. In an @escardio.bsky.social
#EHJ paper we show that a multimarker calculator🌡️outperforms the ESC model. Great leadership by
#DavidJimenez @mmonrealriete.bsky.social
#RIETE! 👇:

tinyurl.com/trpmzbrd

For antithrombotic 💊 in AF+ACS/PCI:
-Many pts have recurrent ischemia or🩸.
-#AUGUSTUS results @dcrinews.bsky.social in @jaccjournals.bsky.social shows:

1.Apixaban ⬇️🩸c/w warfarin w/o ⬆️thrombosis
2. Placebo ⬇️🩸c/w aspirin w/o ⬆️thrombosis
Paper: tinyurl.com/2s4kuy8m
The Editorial: tinyurl.com/4evteweb

When pts have stable #CAD & #AF, do we need both #anticoagulant therapy and #antiplatelet agents? Our collaborative meta-analysis of RCTs shows that monotherapy with anticoagulation ⬇️🩸 without a large increase in ischemic events. @jaccjournals.bsky.social

www.jacc.org/doi/10.1016/...